Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carrie Van Der Weyden

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Leukemia & Lymphoma|June 11, 2015
High-dose thiotepa-based conditioning regimens for relapsed lymphoma involving the central nervous system: from "orphan drug" to a standard-of-care?Carrie van der Weyden, H Miles Prince
Blood Advances|May 14, 2026
On the RAdR in relapsed T-cell lymphomaJoshua M L Casan, Carrie Van Der Weyden
Leukemia & Lymphoma|July 31, 2020
Pralatrexate and angioimmunoblastic T-cell lymphoma: time for a second look?Carrie van der Weyden, Sean Harrop, Henry Miles Prince
Expert Review of Hematology|December 12, 2018
Brentuximab vedotin in T-cell lymphomaCarrie Van Der Weyden, Michael Dickinson, James Whisstock, et al.
Current Oncology Reports|March 25, 2018
Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary SyndromeLouise Photiou, Carrie van der Weyden, Christopher McCormack, et al.
Journal of Personalized Medicine|June 2, 2021
Targeted Approaches to T-Cell LymphomaSean Harrop, Chathuri Abeyakoon, Carrie Van Der Weyden, et al.
Leukemia & Lymphoma|May 14, 2020
Primary cutaneous anaplastic large cell lymphoma and evolving clinical practice: 26 years of skin lesions with locoregional progression to systemic diseaseCrystal Gao, Sean Harrop, Carrie Van Der Weyden, et al.
Ejhaem|May 14, 2025
Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T-cell Lymphoma: Results of a Single-centre Phase 1 Dose-escalation StudyCarrie van der Weyden, Mathias Bressel, Amit Khot, et al.
Expert Opinion on Investigational Drugs|July 13, 2018
IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphomaCarrie Van Der Weyden, Martine Bagot, Paul Neeson, et al.
Leukemia & Lymphoma|September 7, 2022
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphomaLeisa R Watson, Thomas E Lew, Lucy C Fox, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Leukemia & Lymphoma|June 11, 2015
High-dose thiotepa-based conditioning regimens for relapsed lymphoma involving the central nervous system: from "orphan drug" to a standard-of-care?Carrie van der Weyden, H Miles Prince
Blood Advances|May 14, 2026
On the RAdR in relapsed T-cell lymphomaJoshua M L Casan, Carrie Van Der Weyden
Leukemia & Lymphoma|July 31, 2020
Pralatrexate and angioimmunoblastic T-cell lymphoma: time for a second look?Carrie van der Weyden, Sean Harrop, Henry Miles Prince
Expert Review of Hematology|December 12, 2018
Brentuximab vedotin in T-cell lymphomaCarrie Van Der Weyden, Michael Dickinson, James Whisstock, et al.
Current Oncology Reports|March 25, 2018
Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary SyndromeLouise Photiou, Carrie van der Weyden, Christopher McCormack, et al.
Journal of Personalized Medicine|June 2, 2021
Targeted Approaches to T-Cell LymphomaSean Harrop, Chathuri Abeyakoon, Carrie Van Der Weyden, et al.
Leukemia & Lymphoma|May 14, 2020
Primary cutaneous anaplastic large cell lymphoma and evolving clinical practice: 26 years of skin lesions with locoregional progression to systemic diseaseCrystal Gao, Sean Harrop, Carrie Van Der Weyden, et al.
Ejhaem|May 14, 2025
Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T-cell Lymphoma: Results of a Single-centre Phase 1 Dose-escalation StudyCarrie van der Weyden, Mathias Bressel, Amit Khot, et al.
Expert Opinion on Investigational Drugs|July 13, 2018
IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphomaCarrie Van Der Weyden, Martine Bagot, Paul Neeson, et al.
Leukemia & Lymphoma|September 7, 2022
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphomaLeisa R Watson, Thomas E Lew, Lucy C Fox, et al.
Pageof 4